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Abstract
Background:  Multiple sclerosis (MS) is a disorder of the central nervous system (CNS)
characterised by inflammation and neuronal degeneration. It is believed to result from the complex
interaction of a number of genes, each with modest effect. Chemokines are vital to the migration
of cells to sites of inflammation, including the CNS, and many are implicated in MS pathogenesis.
Most of the CC chemokine genes are encoded in a cluster on chromosome 17q11.2-12, which has
been identified in a number of genome wide screens as being potentially associated with MS.
Methods: We conducted a two-stage analysis to investigate the chemokine gene cluster for
association with MS. After sequencing the chemokine genes in several DNA pools to identify
common polymorphisms, 12 candidate single-nucleotide polymorphisms (SNPs) were genotyped in
a cohort of Australian MS trio families.
Results: Marginally significant (uncorrected) transmission distortion was identified for four of the
SNPs after stratification for several factors. We also identified marginally significant (uncorrected)
transmission distortion for haplotypes encompassing the CCL2  and  CCL11  genes, using two
independent cohorts, which was consistent with recent reports from another group.
Conclusion: Our results implicate several chemokines as possibly being associated with MS
susceptibility, and given that chemokines and their receptors are suitable targets for therapeutic
agents, further investigation is warranted in this region.
Background
Multiple sclerosis (MS) is the most common chronic neu-
rological disease in young adults. It is characterised by
inflammation of the central nervous system (CNS),
believed to be the result of an autoimmune reaction
resulting in demyelination and destruction of neural sup-
porting cells [1]. Epidemiological studies suggest a multi-
factorial aetiology for MS, implicating a complex interplay
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between environmental and genetic factors [2]. In the past
ten years, a large number of genome wide screens have
been conducted, including the recent GAMES collabora-
tion (Genetic Analysis of Multiple sclerosis in EuropeanS)
[3]. Multiple regions of potential linkage and association
with MS have been identified, suggesting that genetic pre-
disposition to MS might result from the modest contribu-
tion of many genetic factors, which, if identified, may
present important new therapeutic targets [4].
The inflammatory response that is characteristic of MS
requires the targetted migration of leukocytes into the
CNS, which is under the control of chemokines. Over 40
members of the human chemokine family have been
identified, which act upon a variety of leukocytes via inter-
actions with almost 20 seven-transmembrane domain
chemokine receptors [5]. Chemokines are small mole-
cules of approximately 8–10 kDa in size, and are primarily
classified on the basis of the relative positioning of two
conserved cysteines. In the CC chemokines, the two
cysteines are adjacent, and in the CXC chemokines, a sin-
gle amino acid residue separates the cysteines. Two
smaller subgroups have also been identified; the CX3C
chemokines, and the C chemokines.
Functionally, CC chemokines chemoattract a wide range
of cells, including lymphocytes, dendritic cells, mono-
cytes and some granulocytes [6,7], whilst CXC chemok-
ines are chemoattractant for neutrophils and lymphocytes
[6,7]. There is increasing evidence for chemokines pos-
sessing abilities beyond that of migration, including T-
helper cell subset differentiation [8], T cell costimulation
[9,10], and macrophage and natural killer cell maturation
[11,12].
Substantial evidence supports the involvement of CC
chemokines in the pathogenesis of MS. In the mouse
model of MS, experimental autoimmune encephalomy-
elitis (EAE), knockout of CCL2 leads to resistance to dis-
ease induction [13], whilst CCL3, CCL4 and CCL5 have
all been implicated in EAE development [14,15]. How-
ever, CCL3-knockout mice were found to be fully suscep-
tible to myelin oligodendrocyte glycoprotein (MOG)-
induced EAE [16]. In MS lesions, expression of CC chem-
okines, including CCL2, CCL3, CCL4, CCL5, CCL7 and
CCL8, and their receptors, have been identified on a wide
variety of cells, such as astrocytes, microglia and perivas-
cular T cells [17-22]. In addition, altered levels of CC
chemokines and receptors have been identified in the
serum and cerebrospinal fluid (CSF) of MS patients; some
are elevated (including CCL5), whilst CCL2 is decreased
in the CSF [22-26], possibly due to removal by CCR2-pos-
itive migrating cells as they cross the blood-brain barrier
[27].
Fourteen of the 28 CC chemokine genes are clustered on
chromosome 17q11.2-12 (Figure 1) [28]. This cluster
spans slightly less than 2 Mb, and is split into two sub-
clusters separated by a gap of 1.5 Mb. The 17q11.2-12
region has been implicated in genome-wide screens for
linkage and association with MS [29-34], and in a meta-
analysis of three genome screens, the most significant
nonparametric linkage score was obtained for this region
[35]. The 17q region is also syntenic to an EAE quantita-
tive trait locus on chromosome 10, which includes a
chemokine gene cluster [36], and non-synonymous poly-
morphisms in murine CCL1, CCL2 and CCL12 were iden-
tified as candidates for the eae7 quantitative trait locus
[37].
Candidate gene studies of CC chemokines in MS have not
been extensive. Rather, the majority of studies have
focussed on other diseases. Polymorphisms from several
CC chemokine genes have been variably associated with
diseases such as tuberculosis [38], HIV [39], arthritis [40],
and asthma and atopy [41,42]. The CCR5Δ32 mutation
has been widely studied in MS. Whilst it was found not to
be a general susceptibility factor for MS [43], it may have
effects on age of onset or disease progression [44,45].
More recently, several moderate single-loci and haplo-
Schematic representation of the 17q11.2-12 CC chemokine gene cluster (not to scale) Figure 1
Schematic representation of the 17q11.2-12 CC chemokine gene cluster (not to scale).
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typic associations with MS were identified for single
nucleotide polymorphisms (SNPs) from the CC chemok-
ine gene cluster [46].
It was the aim of our study to conduct candidate gene
analyses for the CC chemokines in order to identify poly-
morphisms and/or haplotypes associated with MS. We
undertook a two-stage analysis. The first stage involved
the scanning of the genes for published (online) and
novel polymorphisms in several DNA pools by DNA
sequencing. From these, 12 candidate SNPs were then
individually genotyped in a cohort of MS trio families in
the second stage. We also sought confirmation of our
findings in an independent cohort of Australian MS fami-
lies. Marginally significant (uncorrected) transmission
distortion was identified for four of the SNPs, as well as
for haplotypes encompassing the CCL2 and CCL11 genes.
Methods
Subjects
For the main study, all sporadic MS cases and parents
(including 373 MS trio families) were recruited by our
facility at the Institute for Immunology and Allergy
Research, Westmead Hospital (Australia). The familial
DNA pool was derived from MS probands from multicase
families obtained from the National Register of Multiple
Sclerosis Families (Rex Simmons, Canberra Hospital, Aus-
tralia). Control individuals were composed of local staff
members and spouses of sporadic MS cases. MS patients
and controls had the same ethnic composition, and were
of similar average age (patients = 50yo; controls =
52.8yo). 90% of MS patients were of northern European
origin, while the remainder were of southern European
origin. The ratio of female to male patients was 4:1; the
control ratio was 1.5:1. Approximately 60% of MS
patients were HLA-DRB1*1501 positive; 73% had relaps-
ing-remitting (RR)-MS, 20% secondary-progressive (SP)-
MS, 5% primary-progressive (PP)-MS, and 2% progressive
relapsing (PR)-MS. An additional cohort of 208 Australian
MS trio families was obtained from the Southern MS
Genetics Consortium for independent validation of our
initial results. All cases were verified as having MS as
defined by the Poser criteria [47], and provided written
informed consent.
Pooled DNA sequencing
DNA was extracted from whole blood using a rapid salting
out method [48]. Methods for the construction of the
DNA pools has been described elsewhere [49]. Four DNA
pools were constructed: 217 HLA-DRB1*1501 positive
sporadic MS patients; 155 HLA-DRB1*1501 negative spo-
radic MS patients; 169 MS probands from multicase fam-
ilies; 185 unrelated, unaffected controls. HLA-
DRB1*1501 status was genotyped using a SYBR Green
assay (Applied Biosystems (ABI)), described elsewhere
[50].
DNA sequencing primers were designed to encompass the
exons of all genes analysed, as well as segments of the
putative promoter region, and often part of the 3' untrans-
lated region (UTR) (see additional file 1:
17qSuppTable1). Where possible, primers were also
designed to maximise coverage of published SNPs, which
were identified from online SNP databases.
DNA sequencing of the chemokine genes was performed
on each of the DNA pools and a single individual,
included for SNP allele frequency correction purposes and
for potential identification of rare SNPs. PCR products for
each gene segment were amplified using the ABI 2× PCR
Master Mix, with 50 ng of genomic DNA and appropriate
amplification primer pairs (Sigma Genosys) to a final
concentration of 5 ng/μL. PCR reactions followed a stand-
ard PCR program: 1 cycle of 95°C for 10 minutes; 35
cycles of 94°C for 30 seconds, 62°C for 30 seconds, and
72°C for 1 minute and 10 seconds; a final elongation step
of 72°C for 10 minutes. PCR products were purified from
the PCR cocktail by use of either the QIAQuick® PCR puri-
fication kit (QIAGEN), or ExoSAP-IT (USB Corporation).
Sequencing reactions were performed using the ABI Big
Dye® Terminator v3.1 Cycle Sequencing Kit. Final samples
were sequenced using an ABI 3100 sequence analyser.
Sequences were viewed using the ABI PRISM™ EditView
software.
Genotyping in Trio Families
SNaPshot
An initial set of seven CC chemokine gene SNPs were
selected for individual genotyping in a cohort of 204 MS
trio families (Table 1): CCL2 -2581, CCL2 -2138, CCL11
67, CCL5 -471, CCL15 -1284, CCL15 136+88 and CCL23
-289. These SNPs were genotyped using the SNaPshot
assay, which allows the genotyping of multiple SNPs
simultaneously in a single-tube multiplexed reaction,
using primer-extension methodology [51] (see additional
file 3: 17qSuppTable3 for SNaPshot primer details for
each of the seven SNPs).
SNaPshot genotyping was performed on the pooled PCR
products of each individual, amplified using either the
ABI 2× PCR master mix, or the Fermentas 2× PCR master
mix (Progen). SNaPshot reactions were optimised in indi-
viduals of known genotype. Between 100–200 ng of DNA
was used from each individual with the appropriate
amplification primer pair (Sigma Genosys) to a final con-
centration of 5 ng/μL. PCR products were amplified using
the standard conditions, as described above. The success-
ful amplification of PCR products was verified on 1% aga-
rose gels. The PCR products for each individual were thenBMC Medical Genetics 2006, 7:64 http://www.biomedcentral.com/1471-2350/7/64
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pooled, and an aliquot purified using ExoSAP-IT (USB
Corporation). To this aliquot was then added 2.5 μL of
SNaPshot Multiplex reagent (ABI), and pooled SNaPshot
primers as defined in Supplementary Table 3, and the
SNaPshot procedure was followed as per the manufac-
turer's instructions (ABI). Samples were then scanned
using an ABI 3100. SNaPshot results were viewed using
the GeneScan™ software (ABI) and genotypes determined
using the GeneMapper™ software package (ABI).
SNPlex™
An additional five CC chemokine gene SNPs were selected
for genotyping in the full cohort of 373 MS trio families
(Table 1): CCL11 -488, CCL8 205, CCL16 -595, CCL14 -
649 and CCL23 316. These SNPs were genotyped using
the SNPlex™ genotyping system (ABI), for which
SUPAMAC (University of Sydney, Australia) were con-
tracted. This system allows high-throughput genotyping
of up to 48 SNPs simultaneously in a single tube using an
oligonucleotide ligation assay. Initially, candidate SNP
details were submitted, after which suitability for the
assay was determined by running the SNPs through an
algorithm. Oligonucleotides were then designed for each
SNP, and applied to the DNA samples (500 ng genomic
DNA). Samples were scanned using an ABI 3730. Geno-
typing results were determined using the GeneMapper™
software package (ABI), utilising an allelic discrimination
cluster analysis to allocate genotype calls with maximum
stringency.
Additional genotyping of validation cohort
Genotyping of the additional cohort of MS trio families
was contracted to the Australian Genome Research Facility
(AGRF; Brisbane, Australia). Only the CCL2  -2138A>T
and  CCL11  -488C>A SNPs were genotyped using the
Sequenom Autoflex Mass Spectrometer. After submission
of SNP details, PCR oligonucleotides were designed and
applied to the DNA samples.
Table 1: Summary of SNPs identified by sequencing of CC chemokine genes in DNA pools that were selected for individual 
genotyping. Other detected SNPs are described in Supplementary Table 2.
Estimated 
minor allele 
frequency
Estimated relative risk
(for minor allele frequency >0.15)
Locus rsID Control pool HLA-DRB1*1501
positive pool
HLA-DRB1*1501
negative pool
Familial pool
CCL2
-2581A>G 1024611 0.5 0.9 0.8 0.7
-2138A>T 1024610 0.3 1.2 1.5 1.5
CCL11
-488C>A 17735961 0.2 1.2 1.2 1.3
67G>A (A>T)+ 3744508 0.1 - - -
CCL8
-572C>T 3138035 0.3 1.1 1.0 1.2
† 205A>C (K>Q)+ 3138038 0.2 0.8 0.8 0.7
CCL5 (-)
-471C>T 2107538 0.2 1.2 1.3 1.1
CCL16 (-)
-595C>A 854680 0.1 - - -
CCL14 (-)
-649T>A 854682 0.2* 1.1* 1.0* 1.4*
CCL15 (-)
-1284A>C 854628 <0.1 - Undetectable -
136+88C>T Novel 0.3 0.8 0.6 0.5
CCL23 (-)
-289A>C 854655 0.2* 0.7* 0.5* 1.0*
316T>C (M>V)+ 1003645 0.2* 1.0* 0.7* 1.0*
All SNPs classified relative to translation start site. Relative risks determined relative to control pool. SNPs in bold were individually genotyped in 
second stage
(-) Gene encoded in anti-sense direction; SNPs reclassified to account for this
+ Coding change in brackets
†The CCL8 205 SNP was originally selected for genotyping by SNPLEX™, but failed the SNPLEX™ algorithm, and was replaced with the CCL8 -
572 SNP
* Heterozygous individual correction applied
rsID: SNP identification numberBMC Medical Genetics 2006, 7:64 http://www.biomedcentral.com/1471-2350/7/64
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Analyses & statistics
Sequencing results from DNA pools and individuals were
compared and scanned for published SNPs and novel pol-
ymorphisms. All SNPs were classified according to the
nomenclature recommended by den Dunnen and Anton-
arakis [52], and are relative to the translation start site. For
genes transcribed in the anti-sense direction (indicated in
Table 1 with (-)), the complementary nucleotide for each
allele was used, and is used throughout this manuscript.
Minor allele frequencies (MAF) of SNPs were estimated by
comparing the relative peak heights of the alleles. Where
the individual was heterozygous for a particular SNP, the
MAF in the DNA pools could be corrected for SNP-specific
variation in peak-height intensity. The significance of dif-
ferences between the MS patient pools and the control
pool was measured by estimated relative risk (ERR) calcu-
lations.
Each SNP was analysed for transmission distortion within
the trios using the transmission disequilibrium test (TDT)
[53]. Analysis was performed using the GENEHUNTER
program [54].
The HelixTree genetics analysis software (Golden Helix
Inc, Bozeman, USA) was used to calculate linkage disequi-
librium (LD) for the 12 SNPs analysed and to determine
haplotypes in parents only. By using the Expectation/Max-
imisation (EM) algorithm, the software was able to calcu-
late probabilities of each haplotype occurring, based on
multi-locus genotypes. It calculated D' and r2  values,
which are accepted measures of LD, and performed a χ2
comparison for each pair of SNPs. HaploBlockFinder [55]
was used to establish the haplotype block structure across
the CC chemokine gene cluster.
TRANSMIT [56] was then used to analyse for haplotype
transmission disequilibrium, estimating χ2  values for
individual haplotypes, as well as global χ2 values for all
haplotypes analysed. Mendelian transmission was
checked using MERLIN [57].
Results
Identification and analysis of SNPs in CC chemokine genes 
by DNA pool sequencing
The CC chemokine genes were scanned using DNA pool
sequencing in order to identify common polymorphisms
in the region, including the potential identification of
novel SNPs, and to establish whether associations might
exist for these SNPs. In all, 50 SNPs were identified across
the CC chemokine gene cluster (a list of all variants iden-
tified is available in the additional file 2:
17qSuppTable2), 48 of which were known; novel SNPs
were detected in CCL8 and CCL15. Five common SNPs
within exons were confirmed, four of which cause codon
changes. Twenty-nine SNPs had MAF >0.15 in the control
pool, designated as 'common' here, and for which we had
statistical power to detect associations for ERR >1.5.
The greater than 90% DNA sequence homology between
CCL3 and CCL3L1, and between CCL4 and CCL4L1, made
it impractical to design specific primers for each of these
genes. Thus, these four genes were not sequenced.
Population genetics of individually genotyped markers
Based on their likely functional significance (codon
changing, putative promoter region, reported functional
significance) and ERR from the pooled DNA sequencing,
12 SNPs were chosen for genotyping in the MS cohort,
either by SNaPshot or SNPlex™ (Table 1). The CCL8 205
SNP was originally chosen for analysis by SNPlex™, but
failed to pass the SNPlex™ algorithm. Thus, it was replaced
with the CCL8 -572 SNP, which is in LD with the original
SNP (International HapMap Project [58]).
Genotype information retrieval for the seven SNPs geno-
typed using SNaPshot was 100%. Genotype information
available for single-locus analysis for the five SNPs geno-
typed by SNPlex™ ranged between 84–87%; losses due to
failed genotyping, and the exclusion of genotypes called
with low stringency. The SNPlex™ genotyping, which is
based on a highly multiplex PCR, was quite sensitive to
DNA quality. Unambiguous genotypes could be deter-
mined using the SNPlex™ calling algorithm, which we
have used at the highest stringency. The genotype frequen-
cies for all SNPs conformed to Hardy-Weinberg equilib-
rium estimates, except for the CCL11  -488 SNP in
mothers. The Mendelian error rate for the seven SNPs was
≤ 2%. Table 2 lists the MAF of the 12 markers as deter-
mined by individual genotyping.
Linkage disequilibrium and haplotypes
The HelixTree genetics analysis software (Golden Helix
Inc, Bozeman, USA) was used to conduct a pair-wise anal-
ysis of LD across the 12 CC chemokine gene markers,
using the parents only. This software calculated both D'
and r2 measures of LD, and the data are represented in Fig-
ure 2. These results were confirmed using the Haploview
software package [59]. Results suggest a clear separation of
the SNPs into two haplotype blocks of moderate to strong
LD, confirmed by HaploBlockFinder [55] (represented in
Figure 2). The first block extended from the CCL2 -2581
SNP to the CCL11 67 SNP; a distance of 33.1 kb. The sec-
ond block extended from the CCL14  -649 SNP to the
CCL23 -289 SNP, but did not include the CCL15 136+88
SNP, which interestingly was not in LD with any of its
neighbouring SNPs. This block extended across 30.9 kb.
The HelixTree software was then used to construct haplo-
types only across the two clear haplotype blocks, in par-
ents only (350–650 individuals; actual numbers variedBMC Medical Genetics 2006, 7:64 http://www.biomedcentral.com/1471-2350/7/64
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for each SNP); and to estimate haplotype frequencies.
Table 2 lists the common haplotypes (frequency >0.05)
across the two haplotype blocks and their frequencies
within the unaffected parents. Four common haplotypes
were identified in the 5' haplotype block, with frequencies
between 0.18 and 0.33. In the 3' haplotype block, three
common haplotypes were identified, but the TATA haplo-
type was the most common by a substantial margin (fre-
quency = 0.76).
Analysis for transmission distortion across single markers 
and haplotypes
Single-locus transmission disequilibrium
Analyses for transmission distortion were undertaken for
the 12 chemokine gene markers in all of the trios, as well
as subgroups stratified based on HLA-DRB1*1501 status,
disease course and gender. Results are listed in Table 3.
No significant transmission distortion was found for any
of the SNPs when analysed in all individuals. Upon strat-
ification, a trend towards excess transmission of the CCL5
-471T allele was found in the HLA-DRB1*1501 negative
group (P(uncorrected) = 0.03). Interestingly, DNA
sequencing had also suggested an increased ERR for the T
allele in the HLA-DRB1*1501 negative pool. For the
CCL14  -649T>A SNP, transmission distortion of the T
allele was found in patients with RR-MS (P(uncorrected)
= 0.03). In contrast, transmission distortion of the A allele
was found in SP-MS patients (P(uncorrected) = 0.02).
Transmission distortion in SP-MS patients was also found
for the CCL23 316C allele (P(uncorrected) = 0.02). For
the CCL23 -289A>C SNP, transmission distortion of the C
allele was found in male MS patients (P(uncorrected) =
0.03). This distortion was accentuated in male patients
with SP-MS (P(uncorrected) = 0.007), however this result
was inconclusive given the small number of individuals in
this group (n = 10 informative transmissions). None of
these results would survive a conservative Bonferroni cor-
rection for multiple comparisons.
Haplotype TDT
Whilst single-locus analyses did not suggest that any of
the SNPs were significantly associated with MS suscepti-
bility, it is conceivable that they may define MS-associated
haplotypes. Using the TRANSMIT [56] software, haplo-
type transmission was evaluated for common haplotypes
(>5% frequency) of decreasing size from either block, as
well as pairwise analyses across all twelve SNPs. Analyses
were conducted only where genotyping information was
available for all individuals across all 12 SNPs (n = 162
LD plot of CC chemokine gene cluster SNPs Figure 2
LD plot of CC chemokine gene cluster SNPs.
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families), with additional trio families removed after
identification of Mendelian inconsistencies.
Table 4 lists common haplotypes for which transmission
distortion was identified. All of these findings were iden-
tified within the 5' haplotype block (CCL2 -2581.CCL2 -
2138.CCL11  -488.CCL11  67). Marginally significant
transmission distortion was found for two four-marker
haplotypes, and several three-marker haplotypes (P ≤
0.05). Marginally significant transmission distortion was
also identified for pairwise analyses for CCL2 -2581.CCL2
-2138 (P(uncorrected) = 0.05) and CCL2 -2138.CCL11 -
488 haplotypes (P(uncorrected) = 0.04). No significant
transmission distortion was found for haplotypes across
the 3' haplotype block.
Verification of haplotype results in an independent cohort
Independent validation of the results discussed above was
sought in an independent cohort of 208 Australian MS
trio families obtained from the Southern MS Genetics
Consortium. It was determined that genotyping the CCL2
-2138A>T and CCL11 -488C>A SNPs was sufficient for
information extraction across the four markers within the
5' haplotype block.
Genotype and minor allele frequencies for both SNPs
were equivalent to those obtained for our cohort, and
were in Hardy-Weinberg equilibrium. LD properties
between the two markers were also in agreement with our
results. No evidence for single-locus transmission distor-
tion was identified for either SNP, supporting our original
findings. Full haplotype transmission data could be
obtained for 169 trios; losses were due to genotyping fail-
ure for either SNP. Two-marker haplotype analysis
revealed slight transmission distortion for the A.C and T.C
haplotypes in the same direction as our original findings,
but the distortion was not significant (Table 4(b)). How-
ever, combining the total datasets of the two cohorts
restored the original trends for transmission distortion for
the A.C and T.C haplotypes (P = 0.05) (Table 4(c)).
Table 2: Common haplotype and minor allele frequencies for SNPs within haplotype blocks in unaffected parents (n = 350–650 
individuals), determined by individual genotyping.
(a) 5' block
CCL2 -2581A>G CCL2 -2138A>T CCL11 -488C>A CCL11 67G>A Haplotype Frequency
Haplotypes
A A C G 0.33
G A C G 0.29
A A A A 0.19
A T C G 0.18
Minor allele frequency
GTAA
0.29 0.19 0.19 0.20
(b) 3' block
CCL14 -649T>A CCL15 -1284A>C CCL23 316T>C CCL23 -289A>C Haplotype Frequency
Haplotypes
TATA 0 . 7 6
A A C C 0.12
A C C C 0.07
Minor allele frequency
ACCC
0.23 0.08 0.20 0.20
(c) Minor allele frequencies 
of remaining SNPs
SNP Minor allele frequency
CCL8 -572C>T T 0.37
CCL5 -471C>T T 0.19
CCL16 -595C>A A 0.22
CCL15 136+88C>T T 0.05BMC Medical Genetics 2006, 7:64 http://www.biomedcentral.com/1471-2350/7/64
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Discussion
In this study, we have analysed the members of the CC
chemokine gene cluster for association with MS. Variant
chemokine expression could diminish or enhance the
inflammatory response characteristic of MS. The majority
of CC chemokine genes are located in a chromosomal
region (17q11.2-12) that has shown suggestive linkage
and association with MS in a number of genome wide
screens [29-34]. Most recently, in a large genome wide
linkage screen, no genome-wide significant results could
be identified beyond the MHC [60]. However, suggestive
linkage was identified on chromosome 17q23. An impor-
tant deduction from this work was that linkage studies are
under-powered to detect modest associations even in
large cohorts.
We utilised a two-stage approach for this study, the first of
which was sequencing of four DNA pools, three com-
posed of MS patients and one control DNA pool across
the 17q11.2-12 CC chemokine gene cluster. This
approach allowed estimation of MAF for all common
(MAF >0.15) SNPs across the CC chemokine genes in our
Australian Caucasian cohort, and identification of two
novel SNPs. This technique has been validated by our
group [61]. Twelve SNPs were chosen for further analysis
by individual genotyping, based on their likely functional
significance (codon changing, location in the putative
promoter region), prevalence (MAF >0.1), and/or uneven
representation between the MS and control pools.
Overall, a large amount of genetic data has been gathered
from pooled DNA sequencing and individual genotyping.
The pooled sequencing provided a close estimate of MAF
for SNPs across the 17q chemokine gene region, and veri-
fied the existence of common SNPs published in online
databases. The individual genotyping data from 350–650
unaffected parents allowed the determination of MAF for
the 12 SNPs chosen for further study, establishment of LD
structure across the region, and calculation of haplotype
frequencies in our unaffected Australian cohort. The MAF
data facilitate power calculations for additional disease-
susceptibility studies, and it and the haplotype data
should prove useful in studies of population variation for
these immunologically important genes. From individual
genotyping, MAF were established for the 12 markers in a
large unaffected cohort (up to 600 unaffected parents),
whilst LD analysis revealed the haplotype block structure
across the cluster, and haplotype frequencies were also
established.
Measurement of transmission distortion for each of the 12
SNPs in MS trios provided some evidence for over-trans-
mission of several of the SNPs after stratification, but
these trends would not survive a conservative correction
for multiple comparisons.
The CCL5 -471C>T SNP, which we found might be asso-
ciated with MS in HLA-DRB1*1501 negative patients, is of
potential functional relevance, as it creates a new tran-
Table 3: Single locus TDT analysis of individually genotyped CC chemokine gene markers.
Locus All families HLA-
DRB1*1501
positive
HLA-
DRB1*1501
negative
RR-MS SP-MS Male Female
T:N P T:N P T:N P T:N P T:N P T:N P T:N P
*CCL2 -2581A>G 79:89 0.4 48:57 0.4 31:32 0.9 51:68 0.1 21:16 0.4 16:13 0.60 63:76 0.3
*CCL2 -2138A>T 56:75 0.1 35:41 0.5 21:34 0.08 41:56 0.1 12:15 0.6 13:13 1 43:62 0.06
CCL11 -488C>A 88:96 0.6 45:59 0.2 43:37 0.5 68:69 0.9 15:17 0.7 20:22 0.8 68:74 0.6
*CCL11 67G>A 71:65 0.6 39:37 0.8 32:28 0.6 54:46 0.4 14:13 0.8 15:15 1 56:50 0.6
CCL8 -572C>T 143:127 0.3 84:78 0.6 59:49 0.3 107:96 0.4 23:22 0.9 28:32 0.6 115:95 0.2
*CCL5 -471C>T 64:70 0.6 45:35 0.3 19:35 0.03 47:50 0.8 14:13 0.9 14:18 0.5 50:52 0.8
CCL16 -595C>A 103:91 0.4 58:53 0.6 45:38 0.4 76:66 0.4 14:19 0.4 19:19 1 84:72 0.3
CCL14 -649T>A 100:88 0.4 64:49 0.2 36:39 0.7 81:56 0.03 9:22 0.02 17:21 0.5 83:67 0.2
*CCL15 136+88C>T 18:10 0.1 11:6 0.2 7:4 0.4 15:6 0.05 2:3 0.7 2:3 0.7 16:7 0.06
*CCL15 -1284A>C 29:27 0.8 21:20 0.9 8:7 0.8 25:17 0.2 2:5 0.3 3:6 0.3 26:21 0.5
CCL23 316T>C 85:90 0.7 54:57 0.8 31:33 0.8 70:58 0.3 8:21 0.02 13:22 0.1 72:68 0.7
*CCL23 -289A>C 62:71 0.4 42:42 1 20:29 0.2 51:46 0.6 9:17 0.1 8:19 0.03 54:52 0.9
T:N = Transmitted:Non-transmitted for major allele
*Markers genotyped using SNaPshot in 204 trio families; HLA-DRB1*1501 positive: 123 trio families; HLA-DRB1*1501 negative: 81 trio families; 
RR-MS: 147 trio families; SP-MS: 42 trio families; Male: 38 trio families; Female: 166 trio families Remaining markers genotyped using SNPlex™; All 
families: 269–296 trio families; HLA-DRB1*1501 positive: 156–176 trio families; HLA-DRB1*1501 negative: 113–120 trio families; RR-MS: 193–218 
trio families; SP-MS: 52–56 trio families; Male: 53–60 trio families; Female: 216–236 trio families. Significant P values in bold. P values are not 
corrected for multiple comparisons.BMC Medical Genetics 2006, 7:64 http://www.biomedcentral.com/1471-2350/7/64
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scription factor binding site [41], and has shown associa-
tions with atopic dermatitis, atopy and asthma [41,42].
CCL5 is an important inflammatory chemokine, with a
range of activities upon eosinophils [62], monocytes and
activated T cells [63,64], and has been identified repeat-
edly in the CNS and CSF of MS patients [19,21,22]. Our
data also identify CCL14 and CCL23 as warranting further
investigation, with marginally significant (uncorrected)
trends towards transmission distortion found in RR-MS
and SP-MS patients for CCL14 -649T>A, and in males for
CCL23 -289A>C. Little is known for either of these chem-
okines, beyond basic functionality, and neither has been
studied with regard to MS pathogenesis. The CCL23  -
289A>C SNP was found to affect a potential SP-1 binding
site using the TRANSFAC database [65].
Upon analysing for haplotype transmission distortion
across the CC chemokine gene cluster, we found sugges-
tive evidence for association of haplotypes encompassing
CCL2 and CCL11 (Table 4), which lie within a haplotype
block spanning 33.1 kb. CCL2 has been implicated in MS
pathogenesis. It is chemotactic for T cells and monocytes
[66,67], is important in the induction of inflammation in
EAE [13], has been identified in MS lesions [17-19], and
in contrast to EAE studies has been associated with remis-
sion of MS [68].
Recently (and subsequent to the completion of our
study), a similar study of polymorphisms across the CC
chemokine gene cluster was conducted by Vyshkina et al
[46]. In this study, 31 SNPs derived from online databases
were selected for genotyping in a variety of individuals.
The basis of selection of SNPs was not discussed. This is in
contrast to our approach, in which an informed decision
for SNP selection was based on several criteria, discussed
above, with a particular focus on SNPs with potential
functional consequences. The SNPs assayed by Vyshkina
et al [46] were predominantly non-coding, with no SNPs
from putative promoter regions. Fifteen SNPs overlapped
with those identified in our pooled DNA sequencing. Two
SNPs, both exonic, were individually genotyped in our
study; the remainder did not pass the first stage. One
exonic SNP was excluded as it was not common, whilst an
exonic SNP in CCL4 was not analysed as this gene was
excluded from our study. Similar to our study, Vyshkina et
al [46] found no strong evidence for association with any
Table 4: Haplotype TDT of CC chemokine gene cluster SNPs.
Haplotype Frequency Transmitted Non-transmitted χ2(1df) P (uncorrected)
(a) Local cohort
5' haplotype block
4-marker haplotypes
CCL2 -2581.CCL2 -2138.CCL11 -488.CCL11 67 (n = 162 trio families)
A.A.C.G 0.33 57.0 85.0 5.50 0.02
A.T.C.G 0.18 61.0 40.0 4.36 0.04
3-marker haplotypes
CCL2 -2581.CCL2 -2138.CCL11 -488 (n = 162 trio families)
A.A.C 0.33 56.0 86.0 6.33 0.01
A.T.C 0.18 61.0 40.0 4.36 0.04
CCL2 -2138.CCL11 -488.CCL11 67 (n = 162 trio families)
A.C.G 0.63 70.1 92.0 2.96 0.09
T.C.G 0.18 60.9 40.0 4.34 0.04
2-marker haplotypes
CCL2 -2581.CCL2 -2138 (n = 204 trio families)
A.A 0.52 89.1 117.1 3.80 0.05
CCL2 -2138.CCL11 -488 (n = 162 trio families)
A.C 0.62 69.2 93.1 3.50 0.06
T.C 0.18 60.8 39.9 4.32 0.04
(b) Independent cohort (n = 169 trio families)CCL2 -2138.CCL11 -488
A.C 0.63 75.1 86.0 0.74 0.4
T.C 0.20 59.9 52.0 0.56 0.5
(c) Combined dataset (n = 331 trio families) CCL2 -2138.CCL11 -488
A.C 0.62 144.4 179.1 3.73 0.05
T.C 0.19 120.6 91.9 3.89 0.05BMC Medical Genetics 2006, 7:64 http://www.biomedcentral.com/1471-2350/7/64
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single locus. In addition, we identified similar LD struc-
ture surrounding CCL2.CCL11 and between CCL14 and
CCL23, and identified haplotypic associations for the
CCL2.CCL11 haplotype block. Whilst the SNPs analysed
in this block were different between the two studies, it
might be assumed that they are subject to the LD within
the block. Thus, whilst we can not specifically say that we
have replicated the haplotype associations of Vyshkina et
al [46], we would suggest that the determination of hap-
lotype tagging SNPs in this block is justified. It was inter-
esting that our TDT analysis was conducted entirely in
sporadic MS cases, whilst that of Vyshkina et al [46] had
an emphasis on familial MS, yet both studies found weak
association for the CCL2.CCL11 haplotype block with MS,
suggestive of a general MS susceptibility factor within this
block. This group has since verified their results in a sec-
ond-phase study [69]. Thus, in a combined population
totalling almost 1000 MS families (331 Australian; 644
North American), the results implicate a haplotype associ-
ation encompassing the CCL2.CCL11 markers.
Conclusion
We have conducted a two-stage analysis of polymor-
phisms across the CC chemokine gene cluster. We identi-
fied novel SNPs in this region, and added further
information to the data available on LD structure and
haplotypes across the cluster. Interestingly, our best sin-
gle-locus findings were for promoter SNPs (CCL5  -
471C>T, CCL14 -649T>A, CCL23 -289A>C), which might
affect the relative expression of these chemokines and lead
to downstream effects on leukocyte migration to the CNS,
and therefore influence MS pathogenesis. We also con-
firmed the potential presence of a haplotypic association
across CCL2 and CCL11. Further validation of the associ-
ation of these SNPs in independent cohorts, and confir-
mation of their functional significance would support
therapeutic targetting of these chemokines and their
receptors.
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